Loading clinical trials...
Loading clinical trials...
Phase 3, Randomized, Placebo-Controlled, Efficacy and Safety Study of VERU-111 for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS).
Conditions
Interventions
VERU-111
Locations
58
United States
Honor Health
Scottsdale, Arizona, United States
St. Bernard's Medical Center
Jonesboro, Arkansas, United States
Velocity Clinical Research
Chula Vista, California, United States
Velocity Clinical Research - San Diego
La Mesa, California, United States
Westchester General Hospital, Research Department
Miami, Florida, United States
James A. Haley Veterans Hospital
Tampa, Florida, United States
Start Date
May 18, 2021
Primary Completion Date
July 6, 2022
Completion Date
July 6, 2022
Last Updated
April 18, 2023
NCT04725110
NCT04537299
NCT04668339
NCT04540484
NCT04691908
NCT04930003
Lead Sponsor
Veru Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions